Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

CD7 is expressed on a subset of normal CD34-positive myeloid precursors.

Kriegsmann K, Löffler H, Eckstein V, Schulz R, Kräker S, Braun U, Luft T, Hegenbart U, Schönland S, Dreger P, Krämer A, Ho AD, Müller-Tidow C, Hundemer M.

Eur J Haematol. 2018 May 24. doi: 10.1111/ejh.13100. [Epub ahead of print]

PMID:
29797671
2.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Mar 25. doi: 10.1002/cyto.b.21636. [Epub ahead of print]

PMID:
29577600
3.

The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.

Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schönland S, Luft T, Ho AD, Dreger P.

Ann Hematol. 2018 Jul;97(7):1241-1250. doi: 10.1007/s00277-018-3288-7. Epub 2018 Mar 16.

PMID:
29549411
4.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

PMID:
29408334
5.

Obesity is a significant susceptibility factor for idiopathic AA amyloidosis.

Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, Müller-Tidow C, Lorenz HM, Schönland SO.

Amyloid. 2018 Mar;25(1):37-45. doi: 10.1080/13506129.2018.1429391. Epub 2018 Jan 24.

PMID:
29364741
6.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

7.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N.

Biol Blood Marrow Transplant. 2018 May;24(5):930-936. doi: 10.1016/j.bbmt.2018.01.006. Epub 2018 Jan 12.

PMID:
29339268
8.

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.

Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J.

Haematologica. 2018 Feb;103(2):336-343. doi: 10.3324/haematol.2017.176073. Epub 2017 Dec 7.

9.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N.

Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.

10.

Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.

Kristen AV, Kreusser MM, Blum P, Schönland SO, Frankenstein L, Dösch AO, Knop B, Helmschrott M, Schmack B, Ruhparwar A, Hegenbart U, Katus HA, Raake PWJ.

J Heart Lung Transplant. 2018 May;37(5):611-618. doi: 10.1016/j.healun.2017.11.015. Epub 2017 Nov 15.

PMID:
29217108
11.

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival.

Pika T, Hegenbart U, Flodrova P, Maier B, Kimmich C, Schönland SO.

Blood. 2018 Jan 18;131(3):368-371. doi: 10.1182/blood-2017-09-806463. Epub 2017 Nov 27. No abstract available.

PMID:
29180400
12.

Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation.

Veelken K, Schönland SO, Gdynia G, Weber T, Blank N, Hegenbart U.

Amyloid. 2018 Mar;25(1):68-69. doi: 10.1080/13506129.2017.1405803. Epub 2017 Nov 23. No abstract available.

PMID:
29166802
13.

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis.

Ochs MM, Fritz T, Arenja N, Riffel J, Andre F, Mereles D, Siepen FAD, Hegenbart U, Schönland S, Katus HA, Friedrich MGW, Buss SJ.

J Cardiovasc Magn Reson. 2017 Nov 9;19(1):87. doi: 10.1186/s12968-017-0402-2.

14.

Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.

Lisenko K, Wuchter P, Hansberg M, Mangatter A, Benner A, Ho AD, Goldschmidt H, Hegenbart U, Schönland S.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1870-1878. doi: 10.1016/j.bbmt.2017.07.015. Epub 2017 Jul 25.

PMID:
28754546
15.

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

Baertsch MA, Hillengass J, Blocka J, Schönland S, Hegenbart U, Goldschmidt H, Raab MS.

Hematol Oncol. 2018 Feb;36(1):210-216. doi: 10.1002/hon.2462. Epub 2017 Jul 7.

PMID:
28685863
16.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

17.

Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.

Kollmer J, Sahm F, Hegenbart U, Purrucker JC, Kimmich C, Schönland SO, Hund E, Heiland S, Hayes JM, Kristen AV, Röcken C, Pham M, Bendszus M, Weiler M.

Neurology. 2017 Aug 1;89(5):475-484. doi: 10.1212/WNL.0000000000004178. Epub 2017 Jul 5.

PMID:
28679600
18.

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).

Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland SO, Kröger N; CLL subcommittee, Chronic Malignancies Working Party.

Br J Haematol. 2017 Aug;178(4):521-533. doi: 10.1111/bjh.14791. Epub 2017 Jun 7.

PMID:
28589551
19.

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.

PMID:
28550043
20.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

PMID:
28550039
21.

Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo.

Annamalai K, Liberta F, Vielberg MT, Close W, Lilie H, Gührs KH, Schierhorn A, Koehler R, Schmidt A, Haupt C, Hegenbart U, Schönland S, Schmidt M, Groll M, Fändrich M.

Angew Chem Int Ed Engl. 2017 Jun 19;56(26):7510-7514. doi: 10.1002/anie.201701761. Epub 2017 May 23.

PMID:
28544119
22.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

23.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
24.

Amyloid in bone marrow smears in systemic light-chain amyloidosis.

Kimmich C, Schönland S, Kräker S, Andrulis M, Ho AD, Mayer G, Dittrich T, Hundemer M, Hegenbart U.

Amyloid. 2017 Mar;24(1):52-59. doi: 10.1080/13506129.2017.1314959. Epub 2017 Apr 23.

PMID:
28434267
25.

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, Hemminki K, Goldschmidt H, Schönland SO, Jauch A.

Haematologica. 2017 Jul;102(7):1281-1290. doi: 10.3324/haematol.2016.160721. Epub 2017 Mar 24.

26.

Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances.

Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1193-1202. doi: 10.1016/j.bbmt.2017.03.009. Epub 2017 Mar 8.

27.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias.

Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M.

Blood Cancer J. 2017 Feb 24;7(2):e537. doi: 10.1038/bcj.2017.19.

28.

Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images-reference values and performance in patients with heart failure and left ventricular hypertrophy.

Arenja N, Fritz T, Andre F, Riffel JH, Aus dem Siepen F, Ochs M, Paffhausen J, Hegenbart U, Schönland S, Müller-Hennessen M, Giannitsis E, Kristen AV, Katus HA, Friedrich MG, Buss SJ.

Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1414-1422. doi: 10.1093/ehjci/jew324.

PMID:
28165128
29.

Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre.

Giusca S, Mereles D, Ochs A, Buss S, André F, Seitz S, Riffel J, Fortner P, Andrulis M, Schönland S, Katus HA, Korosoglou G.

Int J Cardiovasc Imaging. 2017 Jun;33(6):879-888. doi: 10.1007/s10554-017-1065-7. Epub 2017 Jan 30.

PMID:
28138817
30.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.

Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland SO, Kröger N.

Bone Marrow Transplant. 2017 Apr;52(4):552-560. doi: 10.1038/bmt.2016.329. Epub 2017 Jan 23.

PMID:
28112746
31.

Flow in a fibril-forming disease.

Schönland S, Hegenbart U.

Blood. 2017 Jan 5;129(1):7-8. doi: 10.1182/blood-2016-11-746693. No abstract available.

32.

Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis.

Ochs MM, Riffel J, Kristen AV, Hegenbart U, Schönland S, Hardt SE, Katus HA, Mereles D, Buss SJ.

J Am Soc Echocardiogr. 2016 Dec;29(12):1188-1196. doi: 10.1016/j.echo.2016.09.003. Epub 2016 Oct 27.

PMID:
28042785
33.

Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Andrich K, Hegenbart U, Kimmich C, Kedia N, Bergen HR 3rd, Schönland S, Wanker E, Bieschke J.

J Biol Chem. 2017 Feb 10;292(6):2328-2344. doi: 10.1074/jbc.M116.750323. Epub 2016 Dec 28.

34.

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.

Leukemia. 2017 Aug;31(8):1735-1742. doi: 10.1038/leu.2016.387. Epub 2016 Dec 27.

PMID:
28025584
35.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Bone Marrow Transplant. 2017 Mar;52(3):372-380. doi: 10.1038/bmt.2016.282. Epub 2016 Dec 12.

PMID:
27941763
36.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N.

Leuk Lymphoma. 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.

37.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

38.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N.

Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27.

39.

Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Lisenko K, Schönland SO, Jauch A, Andrulis M, Röcken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M.

Cancer Med. 2016 Jul;5(7):1464-72. doi: 10.1002/cam4.725. Epub 2016 Apr 25.

40.

Polymorphism of Amyloid Fibrils In Vivo.

Annamalai K, Gührs KH, Koehler R, Schmidt M, Michel H, Loos C, Gaffney PM, Sigurdson CJ, Hegenbart U, Schönland S, Fändrich M.

Angew Chem Int Ed Engl. 2016 Apr 4;55(15):4822-5. doi: 10.1002/anie.201511524. Epub 2016 Mar 8.

41.

Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients.

Freudenthaler S, Hegenbart U, Schönland S, Behrens HM, Krüger S, Röcken C.

Virchows Arch. 2016 May;468(5):569-77. doi: 10.1007/s00428-016-1916-y. Epub 2016 Feb 25.

42.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

43.

[Causes and treatment of systemic amyloidosis].

Blank N, Hegenbart U, Schönland S.

Z Rheumatol. 2016 Mar;75(2):141-50. doi: 10.1007/s00393-015-0024-8. Review. German.

PMID:
26768274
44.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N.

Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Review.

45.

Potential therapeutic targets in plasma cell disorders: A flow cytometry study.

Lisenko K, Schönland S, Hegenbart U, Wallenwein K, Braun U, Mai EK, Hillengass J, Goldschmidt H, Jauch A, Ho AD, Raab M, Hundemer M.

Cytometry B Clin Cytom. 2017 Mar;92(2):145-152. doi: 10.1002/cyto.b.21351. Epub 2016 Feb 3.

46.

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.

Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2015 Dec;50(12):1542-50. doi: 10.1038/bmt.2015.186. Epub 2015 Sep 14.

PMID:
26367221
47.

Reply to R. Warsame et al.

Bochtler T, Hegenbart U, Kunz C, Benner A, Schönland SO.

J Clin Oncol. 2015 Nov 20;33(33):3976-7. doi: 10.1200/JCO.2015.63.2141. Epub 2015 Aug 31. No abstract available.

PMID:
26324370
48.

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.

Hahn M, Böttcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Schulz R, Ritgen M, Schmitt T, Tran TH, Görner M, Herth I, Luft T, Schönland S, Witzens-Harig M, Zenz T, Kneba M, Ho AD, Dreger P.

Bone Marrow Transplant. 2015 Oct;50(10):1279-85. doi: 10.1038/bmt.2015.150. Epub 2015 Jul 6.

PMID:
26146810
49.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.

Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, López-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, KrÖger N, Garderet L.

Bone Marrow Transplant. 2015 Jun;50(6):802-7. doi: 10.1038/bmt.2015.45. Epub 2015 Mar 23.

PMID:
25798673
50.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559

Supplemental Content

Loading ...
Support Center